Clinical Development

Biosplice Therapeutics has designed an unprecedented compendium of new chemical entities which selectively bind to specific members of the CLK/DYRK family and feature drug-like properties amenable to local or systemic administration and CNS exposure.

Biosplice is leveraging the broad therapeutic potential of alternative splicing modulation in musculoskeletal diseases, immunology/inflammation, and oncology.

Biosplice has established clinical proof-of-concept for therapeutic modulation of alternative splicing with the development of lorecivivint, targeting osteoarthritic disease progression by inhibition of alternative splicing-dependent Wnt pathway protein production. Similarly, our clinical trials in oncology center on pan-CLK and DYRK inhibition for therapeutic modulation of alternative splicing.